Market Research Logo

Generics in the United Kingdom

Generics in the United Kingdom

Summary

Generics in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the United Kingdom generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The market value is evaluated at ex-factory prices.

Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.

Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.

Please note that any volumes of 1 (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.

All currency conversions were calculated at constant average annual 2016 exchange rates.

The UK generics market had total revenues of $7,038.6m in 2016, representing a compound annual growth rate (CAGR) of 6.3% between 2012 and 2016.

Market consumption volume increased with a CAGR of 2% between 2012 and 2016, to reach a total of 87.1 % in 2016.

Market growth will accelerate as a result of funding, an ageing population and expiration of patents.

Scope

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United Kingdom
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United Kingdom
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom generics market with five year forecasts by both value and volume
Reasons to buy
  • What was the size of the United Kingdom generics market by value in 2016?
  • What will be the size of the United Kingdom generics market in 2021?
  • What factors are affecting the strength of competition in the United Kingdom generics market?
  • How has the market performed over the last five years?
  • How large is the United Kingdom’s generics market in relation to its regional counterparts?


Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan N.V.
Novartis AG
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: United Kingdom generics market value: $ million, 2012-16
Table 2: United Kingdom generics market volume: % of total pharma volume, 2012-16
Table 3: United Kingdom generics market geography segmentation: $ million, 2016
Table 4: United Kingdom generics market value forecast: $ million, 2016-21
Table 5: United Kingdom generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan N.V.: key facts
Table 7: Mylan N.V.: key financials ($)
Table 8: Mylan N.V.: key financial ratios
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Teva Pharmaceutical Industries Limited: key facts
Table 13: Teva Pharmaceutical Industries Limited: key financials ($)
Table 14: Teva Pharmaceutical Industries Limited: key financial ratios
Table 15: United Kingdom size of population (million), 2012-16
Table 16: United Kingdom gdp (constant 2005 prices, $ billion), 2012-16
Table 17: United Kingdom gdp (current prices, $ billion), 2012-16
Table 18: United Kingdom inflation, 2012-16
Table 19: United Kingdom consumer price index (absolute), 2012-16
Table 20: United Kingdom exchange rate, 2012-16
List of Figures
Figure 1: United Kingdom generics market value: $ million, 2012-16
Figure 2: United Kingdom generics market volume: % of total pharma volume, 2012-16
Figure 3: United Kingdom generics market geography segmentation: % share, by value, 2016
Figure 4: United Kingdom generics market value forecast: $ million, 2016-21
Figure 5: United Kingdom generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in the United Kingdom, 2016
Figure 7: Drivers of buyer power in the generics market in the United Kingdom, 2016
Figure 8: Drivers of supplier power in the generics market in the United Kingdom, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016
Figure 11: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016
Figure 12: Mylan N.V.: revenues & profitability
Figure 13: Mylan N.V.: assets & liabilities
Figure 14: Novartis AG: revenues & profitability
Figure 15: Novartis AG: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report